Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Ordinary Share $0.00001 par value
-
Shares outstanding
-
50,588,235
-
Total 13F shares
-
49,596,818
-
Share change
-
+1,071,921
-
Total reported value
-
$927,239,223
-
Put/Call ratio
-
0%
-
Price per share
-
$18.71
-
Number of holders
-
167
-
Value change
-
+$22,675,435
-
Number of buys
-
96
-
Number of sells
-
63
Institutional Holders of Theravance Biopharma, Inc. - Ordinary Share $0.00001 par value (TBPH) as of Q4 2025
As of 31 Dec 2025,
Theravance Biopharma, Inc. - Ordinary Share $0.00001 par value (TBPH) was held by
167 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
49,596,818 shares.
The largest 10 holders included
Madison Avenue Partners, LP, Weiss Asset Management LP, Newtyn Management, LLC, BlackRock, Inc., Irenic Capital Management LP, VANGUARD GROUP INC, D. E. Shaw & Co., Inc., ACADIAN ASSET MANAGEMENT LLC, STATE STREET CORP, and ARROWSTREET CAPITAL, LIMITED PARTNERSHIP.
This page lists
167
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.